Tilray Brands Inc. has achieved a groundbreaking regulatory milestone in Italy, securing the first-ever authorization from the Italian Ministry of Health to distribute medical cannabis flower for therapeutic use. This approval allows Tilray Medical, a division of Tilray Brands, to introduce three new varieties of medical cannabis in Italy: Tilray THC 25%, Tilray THC 18%, and Tilray THC 9% / CBD 9%. As the first company in Italy to receive such authorization, Tilray continues to expand its leadership in the European medical cannabis market, which includes operations in Germany, Portugal, Poland, and the United Kingdom. This development represents a significant step in enhancing patient access to high-quality, EU-GMP certified cannabinoid-based therapies across Italy.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。